Press release content from PR Newswire. The AP news staff was not involved in its creation.
OncoSec Medical Announces Proposed Public Offering of Common Stock
January 20, 2021 GMT
OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)
PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering will be offered by O
Share this article
Share this article
PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company s lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug/device combination products, as well as their established oncology sales force in the U.S.
Daniel O Connor, President and Chief Executive Officer of OncoSec, stated, Sirtex is a strong company with significant experience in the sales and marketing of drug/device combination products to treat cancer. This deal provides OnocSec with the potential to commercialize TAVO with a highly skilled U.S. sales force in this
OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma
News provided by
Share this article
Share this article
PENNINGTON, N.J. and SAN DIEGO, Jan. 8, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ) today announced the first patient was dosed in OMS-104, an investigator-initiated Phase 2 trial evaluating TAVO™ (tavokinogene telseplasmid), the Company s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy administered using its gene delivery platform (gene electrotransfer), in combination with the anti-PD-1 checkpoint inhibitor OPDIVO
® (nivolumab) as a neoadjuvant therapy prior to surgery in patients with operable, locally or regionally advanced melanoma. The trial is designed to evaluate if the addition of TAVO can improve clinical outcomes already observed when using nivolumab alone as a neoadjuvant therapy.